Related Experiment Video
Updated: Aug 6, 2026
10:00
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
[Dysthyroidism in patients treated with interferon alpha]
P Chédin1, P Chanson, L Duranteau
1Service de Médecine interne, Hôpital Lariboisière, Paris.
Presse Medicale (Paris, France : 1983)
|November 19, 1994
Summary
Alpha-interferon (alpha-IFN) treatment can lead to autoimmune thyroid disease in approximately 1 in 10 patients, manifesting as hypothyroidism or hyperthyroidism. Close thyroid function monitoring is recommended during alpha-IFN therapy.
Area of Science:
- Immunology
- Endocrinology
- Oncology
Context:
- Alpha-interferon (alpha-IFN) exhibits antiviral properties and modulates immune responses.
- Patients with cancer or chronic viral hepatitis are often treated with alpha-IFN.
- Autoimmune thyroid dysfunction is a potential side effect of alpha-IFN therapy.
Purpose:
- To determine the prevalence, clinical course, and predictive factors of autoimmune dysthyroidism in patients receiving alpha-IFN.
- To analyze the types of thyroid dysfunction induced by alpha-IFN.
- To investigate potential pathogenic mechanisms of alpha-IFN-induced thyroid disease.
Summary:
- A meta-analysis of 8 studies involving 573 patients found that 8.7% (47/542) developed dysthyroidism (hypothyroidism, hyperthyroidism, or biphasic) with a mean onset of 9 months.
- Prevalence of antithyroglobulin and/or antimicrosomal antibodies was 13.7%, with lower prevalence for anti-TSH receptor antibodies.
- Pathogenesis may involve alpha-IFN-induced antithyroid antibodies or altered HLA antigen expression on thyrocytes, potentially leading to autoimmune activation.
Impact:
- Alpha-IFN can induce thyroid dysfunction in about 10% of treated patients, likely through autoimmune mechanisms.
- Antithyroid antibodies have a modest positive predictive value (60%) but a high negative predictive value (93%) for predicting dysthyroidism.
- Regular thyroid function monitoring is crucial for patients undergoing alpha-IFN treatment to detect and manage potential adverse effects.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...